

Thank you to our exhibitors

Our exhibitors have paid for stand space only and have had no other involvement in the arrangements for or content of this meeting.

MSD Oncology



For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions, and advance the prevention and treatment of diseases that threaten people and animals around the world.

Novartis Oncology



Novartis Oncology are passionate about the discovery and development of innovative medicines, and seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients. It has an extensive portfolio of oncology, haematology and rare disease medicines. Its broad pipeline includes many new molecular entities targeting key molecular pathways in cancer biology.

With a decade of success in oncology drug development Novartis Oncology recognises the value of its connections within the oncology community and their importance to innovation. They have an ethos of working together with the community to explore novel compounds in clinical development, many with potential best-in-class status. For more information, visit www.novartis.co.uk

IGEA



Through extensive research, IGEA developed CLINIPORATOR™ for delivering electrochemotherapy, a minimally invasive treatment for cutaneous and subcutaneous metastases of melanoma and non-melanoma skin cancers. Electrochemotherapy has been recognised by NICE as an important treatment option for patients and clinicians where other treatment options may have been exhausted. IGEA is committed to improving patients' lives and treating them earlier in their disease.

Bristol-Myers Squibb



Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients overcome serious diseases. For more information about Bristol-Myers Squibb, visit www.b-ms.co.uk.

Crawford Healthcare



Crawford Healthcare is a specialist pharmaceutical company dedicated to making effective dermatological treatments available to healthcare professionals and consumers. By working with partner companies who are leaders in their respective fields and markets, they are able to offer innovative and valuable treatments and diagnostics for a range of skin conditions. Crawford's SunSense range includes sunscreens for everyone. Visit www.crawfordhealthcare.com/skincare.

Skcin



Skcin is a national skin cancer charity, pioneering educational intervention and prevention into skin cancer. Its primary objectives are to:

- Raise awareness of skin cancer through education, promoting prevention and early detection
- To engage higher risk target groups via bespoke educational initiatives
- To ensure continued development, longevity and participation in our national accreditation schemes
- To campaign for change, make a difference and save lives.

Skcin supplies hospitals, CCGs and primary schools with over 1 million of its comprehensive Skin Cancer and Sun Safety booklets and posters to underpin its objective of raising awareness in the UK. It has developed and runs three national accreditation schemes: Sun Safe Nurseries, Sun Safe Schools and Sun Safe Workplaces. The nursing community and dedicated Ambassadors support its work in schools and workplaces. In 2018 Skcin will be launching an exciting new accreditation to help educate and collaborate with key professional industries.

Amgen



Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need, and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world, and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com / www.twitter.com/amgen

Galderma



Created in 1981, Galderma is now present in over 100 countries, with an extensive product portfolio of medical solutions to treat a range of dermatological conditions. The company partners with healthcare professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in the research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

For more information, please visit www.galderma.com

23 and 24 November 2017 | Hilton Metropole, Birmingham



BASCSN 2017 ANNUAL CONFERENCE

Dear Colleague,

On behalf of the BASCSN Board, I am delighted to welcome you to the BASCSN Annual Conference 2017 and to Birmingham.

The conference is a great opportunity to learn, develop our skills, network with colleagues, and share and discuss ideas. It also counts towards your CPD hours and NMC revalidation.

The role of the Skin Cancer Specialist Nurse is growing and it is an exciting time to be practising in this area. The conference programme reflects the diverse roles we have and the wide range of conditions and patients we manage.

BASCSN is here to support you in your day-to-day practice and in your continuing development as a specialist nurse. BASCSN also gives you a voice at a national level through our participation in consultations and policy-making. It is your organisation and the AGM (after lunch on Friday) is an opportunity to tell us what you want from the Association. The open session in the afternoon is also an opportunity to raise issues, ask for advice or share any concerns.

Our sponsors make an important contribution to the meeting and we value their ongoing support for BASCSN. I do hope you will visit their stands and have a chat.

Thank you for coming to Birmingham – I hope you enjoy the meeting.

Kind Regards,

Clair

Clair McGarr
BASCSN Chair

BASCSN
SKIN CANCER SPECIALIST NURSES

Programme


Thursday 23 November – The Terrace Room

6.45pm	Meet for a drink and networking in the Terrace Room
7.15pm	Mind full or mindful? – Sally Cherry
8.15pm	Dinner

Friday 24 November – The Terrace Room

8.30am	Registration
9.00-9.30	Latest developments in Merkel cell carcinoma – Neil Steven, University Hospitals, Birmingham
9.30-10.00	Advanced SCC – Steven Watkins, University Hospitals, Birmingham
10.00-10.30	The new AJCC staging – Jerry Marsden
10.30-11.00	Coffee in the Colonial Room
11.00-11.30	Immunotherapy – managing the risks to gain the benefits – Jackie Hodgetts, The Christie Hospital, Manchester
11.30-12.00	The challenge of bringing sun safety education to the public: apps, roadshows and bakes – British Association of Dermatologists
12.00-12.30	Social media and patient support – the good, the bad and the ugly – Mel Jones
12.30-1.30	Lunch in the Colonial Room
1.30-2.00	BASCSN AGM
2.00-2.30	Interventions for the early detection of skin cancer – Alex Effah, University of Leeds
2.30-3.00	A digital melanoma patient registry – Mark Larkin
3.00-3.30	Issues, advice, challenges and opportunities – open mic discussion
3.30-3.45	Summary and close

Our Speakers



Sally Cherry

Sally has worked as a trainer, coach and training manager in various organisations including charities, local authorities and the probation service. Sally discovered mindfulness when she was facing a period of acute stress during a family crisis, and credits it with helping her to survive and thrive at that time. She now has a regular personal mindfulness practice. Sally later went on to train as a teacher with Breathworks, one of the leading mindfulness organisations in the UK. She runs community-based courses and has also taught courses for offenders and people with multiple sclerosis. She has also taught mindfulness one-to-one, has incorporated mindfulness into leadership coaching, and supervises other mindfulness teachers. Sally is a member of the UK Register of Mindfulness Teachers. www.sallycherryassociates.co.uk



Steven Watkins

Steven is a Consultant Clinical Oncologist at University Hospitals Birmingham NHS Trust, specialising in the treatment of skin and lung cancer. He is the clinical lead for skin cancer radiotherapy and non-melanomatous skin cancer chemotherapies, and is Honorary Lecturer at the University of Birmingham. After completing his postgraduate specialist training in London, he moved to Birmingham in 2015 to take up his current post, which includes active involvement in the regional Skin SMDT, research trials/programs and also – the best part, in his opinion – treating actual patients!

Our Speakers Cont.



Neil Steven

Neil is an Academic Consultant Oncologist at University Hospital and the University of Birmingham. He treats patients with advanced skin cancer, melanoma and Merkel cell carcinoma (MCC), seeking to offer access to trials and cutting-edge therapeutics where possible. He is a clinical trialist with translational expertise in early phase trials, rare cancers, immunotherapy for cancer and virus-associated malignancy. Neil is Clinical Lead for skin cancer trials for the West Midlands NIHR Clinical Research Network, a member of the NCRI Skin Cancer Clinical Studies Group, and a member of the International Rare Cancers Initiative. He is national chief investigator for the Rational MCC trial, addressing uncertainty in treating primary MCC, and translational lead for the UKMMC01 trial, treating metastatic MCC.



Jerry Marsden

Jerry was a Consultant Dermatologist at University Hospital Birmingham from 1987 to 2013, with an interest in general skin oncology, and a specific interest in the management of stage 1 to stage 3 melanoma. In addition to a continuing interest in skin cancer, he is now working as a commercial flight instructor with an interest in the medical and aviation safety interface.



Jackie Hodgetts

Jackie is a Nurse Clinician at The Christie Hospital in Manchester, where she has worked since 1988. She was initially employed as a Research Nurse, working with lung cancer and melanoma patients. In 2009 she completed a Master's degree in Clinical Practice, and since then has worked with melanoma patients, assessing and supporting them through treatment, as well as managing their toxicities. Jackie has been involved in multiple trials of melanoma treatments, including the early studies of BRAF inhibitors and other targeted therapies. She was also involved in early studies with CTLA-4 and anti-PD-1/PD-L1 antibodies, and has since treated many patients with these therapies. Consequently she has developed expertise in melanoma treatments and the management of their side-effects



The British Association of Dermatologists

Established in 1920, the British Association of Dermatologists (BAD) is a charity whose objectives are the practice, teaching, training and research of dermatology. It works with the Department of Health, patient bodies and commissioners across the UK, advising on best practice and the provision of dermatology services across all service settings. The BAD works with many other organisations to achieve its aims of supporting patients and improving standards. These include patient support groups, special interest groups, international dermatology groups and skin charities.



Mel Jones

After training as a research physicist, Mel's first jobs were in pharmaceutical and cosmetics manufacturing management. However, the majority of his career was spent running factories and distribution centres for a large American multinational consumer products company. After retiring he volunteered for the Princes Trust, Aberystwyth University and Shropshire Education Authority. Originally diagnosed with melanoma in 1995, Stage 3 in 1996, Mel was NED for 18 years before his disease returned in late 2014. Since then, he has been a patient advocate and represented Melanoma UK as a patient expert at two NICE new technology appraisals. Currently Mel is stage 4 with stable disease.



Alex Effah

Alex trained as a nurse at University of Portsmouth in 1995. He worked in orthopaedics, geriatrics and dermatology, and then as a dermatology research nurse for one year. He enrolled for a part-time MSc in Public Health at the University of Brighton in 2002 and completed in June 2005. His dissertation was a grounded theory study about the skin problems of intravenous drug users (IDUs) in Hampshire. Alex then joined Portsmouth City Council to support the health and skin problems of IDUs. He co-authored three confidential reports on IDUs commissioned by the Home Office and the Hampshire Constabulary. Alex completed a PhD at Bournemouth University in 2013 and works as a Research Fellow at the University of Leeds, where he is involved in research involving skin issues.



Mark Larkin

Mark founded Vitaccess in 2014, after more than 15 years in market access consulting, with the aim of harnessing the power of digital technology to better represent the voice of patients in drug development and market access. Mark has extensive experience in evidence generation strategy development across a broad range of indications. He has led several registry projects using the Vitaccess platform, MyRealWorld™, including the Melanoma UK digital registry. Launched in October 2017, this groundbreaking project, co-created with patients, brings together the melanoma community to study treatment of melanoma in the real-world to improve care.